Jeffrey Heier
Chief Scientific Officer, Ocular Therapeutics · University of Miami/Jackson Health System
Credentials: · · ·
History
- Present
Ophthalmic Consultants of Boston Inc
- 1996–1997
- 1990–1994
- 1989–1990
Preliminary or Transitional Year
1985–1989
Research
Ranibizumab for neovascular age-related macular degeneration
New England Journal of Medicine · 2006 · 4,838 citations
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
New England Journal of Medicine · 2006 · 2,920 citations
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Ophthalmology · 2012 · First of 21 authors · 2,034 citations
- DB
46 papers · 4 as a resident
- DB
38 papers
30 papers
- RV
26 papers
- CW
21 papers
- CS
16 papers
16 papers · 4 as a resident
- AK
15 papers
Clinical trials
- 2017–2021
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
Principal investigator · Completed · Phase 1, Phase 2
REGENXBIO Inc.
- 2015–2019
IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD
Principal investigator · Completed · Phase 2
Jeffrey S Heier
- 2015–2017
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
Principal investigator · Completed · Phase 2
Roger Goldberg, M.D., MBA
- 2013–2015
A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment
Principal investigator · Completed · Phase 1
Jeffrey S Heier